ATM protein and p53-serine 15 phosphorylation in ataxia-telangiectasia (AT) patients and at heterozygotes by Delia, D et al.
Ataxia telangiectasia (AT) is a rare autosomal recessive multi-
systemic disorder associated with an elevated risk of malignancy,
primarily leukaemias and lymphomas (Boder, 1985). It is esti-
mated that up to 1% of the general population are heterozygous
carriers of AT mutations and, albeit asymptomatic, these individ-
uals have an increased predisposition to cancer in adulthood (Swift
et al, 1991).
The gene responsible, ATM (ataxia telangiectasia mutated),
encodes a nuclear 350 kDa phosphoprotein (Savitsky et al, 1995a,
1995b) containing a carboxy terminus phosphatidylinositol 3-
kinase (Pl-3 kinase) catalytic domain shared by members of a
superfamily of large eukaryotic proteins involved in intracellular
signalling, DNA-damage induced cell cycle checkpoints, DNA
repair and recombination (Meyn, 1995; Hoekstra, 1997). In the
DNA-damage response pathway, ATM acts upstream of p53 to
induce cell cycle arrest at the G1/S and G2/M boundaries and a
slowing of the S-phase (Hoekstra, 1997). Signalling by ATM
involves interactions with and phosphorylation of critical mole-
cules, including the mitotic checkpoints Chk1 and Chk2 (Sanchez
et al, 1997; Walworth et al, 1997), and p53 (Watters et al, 1997;
Westphal et al, 1997; Banin et al, 1998; Canman et al, 1998).
AT patients are affected by a wide spectrum of homozygous or
compound heterozygous germ line mutations of the ATM gene,
primarily deletions or insertions that inactivate the ATM protein
(Savitsky et al, 1995a; Gilad et al, 1996; Lakin et al, 1996; Wright
et al, 1996). ATM gene mutations have also been found in T-cell
prolymphocytic leukaemia patients with no family history of AT
and in non-Hodgkin’s lymphomas (Vorechovsky et al, 1997), but
in contrast to AT, these mutations are somatic, mostly missense
and frequently associated with loss of the normal allele.
The abnormal responses of AT cells to ionizing radiation
include increased chromosomal breaks and radioresistant DNA
synthesis (Stilgenbauer et al, 1997), impaired p53-dependent
arrest in G1 and other cell cycle checkpoint defects (Canman et al,
1994; Thacker 1994; Takagi et al, 1998) that can be corrected by
ectopic expression of a functional ATM protein (Khanna et al,
1995; Ziv et al, 1997). Cultured fibroblasts and lymphocytes from
AT heterozygotes exhibit chromosomal radiosensitivity values
intermediate between normal and AT (West et al, 1995; Scott et al,
1996; Shigeta et al, 1999), indicating a partial impairment of the
ATM-dependent DNA damage-response pathway and suggesting a
link between increased incidence of cancer and dysfunctional
response to low-dose radiation exposure among AT heterozygotes.
We have produced anti-ATM antibodies to analyse the relation-
ship between ATM protein expression and regulation of the 
ATM-dependent G1 cell cycle checkpoint and p53-Ser 15 phos-
phorylation in AT patients and heterozygotes. We report that the
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Summary ATM (ataxia-telangiectasia mutated) gene plays a central role in the DNA-damage response pathway. We characterized the ATM
protein expression in immortalized cells from AT and AT-variant patients, and heterozygotes and correlated it with two ATM-dependent
radiation responses, G1 checkpoint arrest and p53-Ser 15 phosphorylation. On Western blots, the full-length ATM protein was detected in
eight of 18 AT cases, albeit at 1–32% of the normal levels, whereas a truncated ATM protein was detected in a single case, despite the
prevalence among cases of truncation mutations. Of two ataxia without telangiectasia [A-(T)] cases, one expressed 20% and the other ~70%
of the normal ATM levels. Noteworthy, among ten asymptomatic heterozygous carriers for AT, normal amounts of ATM protein were found in
one and reduced by 40–50% in the remaining cases. The radiation-induced phosphorylation of p53 protein at serine 15, largely mediated by
ATM kinase, was defective in AT, A(-T) and in 2/4 heterozygous carriers, while the G1 cell cycle checkpoint was disrupted in all AT and A(-T)
cases, and in 3/10 AT heterozygotes. Altogether, our study shows that AT and A(-T) cases bearing truncation mutations of the ATM gene can
produce modest amounts of full-length (and only rarely truncated) ATM protein. However, this limited expression of ATM protein provides no
benefit regarding the ATM-dependent responses related to G1 arrest and p53-ser15 phosphorylation. Our study additionally shows that the
majority of AT heterozygotes express almost halved levels of ATM protein, sufficient in most cases to normally regulate the ATM-dependent
DNA damage-response pathway. © 2000 Cancer Research Campaign
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AT and atoxia without telangiectasia [A(-T)] whereas the truncated
ATM protein is rarely detectable. Interestingly, compared to
normal controls, most AT heterozygotes exhibit reduced levels of
ATM protein. We also show that p53-Ser15 phosphorylation,
largely mediated by the kinase activity of ATM, is markedly
reduced in AT and A(-T), even in cases with detectable ATM
protein. Finally, cell cycle analysis 24 h post-irradiation show a G1
checkpoint defect in all AT, A(-T) and in some heterozygotes.
MATERIALS AND METHODS
Cell lines, irradiation and cell cycle analysis
Peripheral blood mononuclear cells (PBMC) from normal donors,
AT patients and relatives were immortalized with the supernatant
of the Epstein–Barr virus (EBV)-producing cell line B95-8 and
grown at 37°C in 5% carbon dioxide in RPMI-1640 (Bio-Wittaker,
Walkersville, MD, USA) plus 15% heat-inactivated fetal calf
serum, 100 U ml–1 penicillin, 100 mg ml–1 streptomycin, 2 mmol l–1
glutamine. PBMC were activated by treatment for 96 h with 1 nM
TPA (Sigma, St Louis, MO, USA) and 0.5 mg ml–1 ionomycin
(Calbiochem, San Diego, CA, USA) as described (Delia et al,
1984). Irradiations were performed by an IBL437CO instrument
with a 137Cesium source providing 798 cGy min–1. Control samples
were held at room temperature for the duration of the irradiation.
For cell cycle analysis, samples were resuspended in phosphate-
buffered saline (PBS) plus 0.1% saponine and 1 mg ml–1 RNAase
(Sigma), incubated for 20 min at 37°C, stained with 25 mg ml–1
propidium iodide (Sigma) and analysed (20 000 cells USA per
histogram) by flow cytofluorimetry (FACSvantage, Becton-
Dickinson, Palo Alto, CA, USA), as reported (Delia et al, 1997).
Analysis of ATM gene mutations
Mutations were identified by restriction endonuclease fingerprint
(REF) (Gilad et al, 1998) or protein truncation test (PTT).
Segregation analysis on AT relatives were performed by means of
reverse transcription PCR (RT-PCR), restriction and Heteroduplex
analyses in order to identify the heterozygotes (Prudente et al,
1998). The quantification, in some cases, of the mutant and wild-
type ATM alleles was performed by RT-PCR using primers
flanking the ATM mutation and primers for gluceraldehyde 3-
phosphate dehydrogenase (GAPDH) for normalization.
Recombinant protein, antibody preparation, SDS-PAGE,
immunoblot analysis
The cDNA sequence of ATM corresponding to amino acids 1–150,
amplified by RT-PCR from mRNA derived from normal cells, was
cloned in-frame with a 6 ´ Hist-tag sequence in the expression
vector pTrc-His-B (Invitrogen, San Diego, CA, USA). After trans-
formation with the resulting pTrc-His-ATM-N plasmid and 6 h
induction with 100 mM isopropylthio-(-D-galactoside), bacteria
were lysed in 6 M urea, sonicated, centrifuged and the recombinant
protein was purified from the supernatant by a TALON column
(Clontech, Palo Alto, CA, USA) and 20–100 mM imidazole
elution. Sera from rabbits and mice immunized with the recombi-
nant protein were affinity-purified. Cell extracts were prepared as
described (Delia et al, 1997), by lysing 5 ´ 106 cells in 200 ml
buffer containing 125 mM Tris–HCl pH 6.8, 5% sodium dodecyl
sulphate (SDS). After boiling for 2 min and addition of the
inhibitors 1 mM phenylmethyl sulphexyl fluoride (PMSF), 
10 mg ml–1 pepstatin, 100 KIU ml–1 aprotinin, 10 mg ml–1 leupeptin
(all from Calbiochem) and 1 mM sodium orthovandate (Sigma),
lysates were sonicated for 20 s, centrifuged, quantitated by the
micro-BCA method (Pierce, Rockford, IL, USA) and fractionated
(100 mg per lane) on a two-gradient SDS polyacrylamide gel
electrophoresis (SDS-PAGE) (bottom 4 cm: 10% gel, acryl-
amide/bis-acrylamide ratio 29:1; top 6 cm: 5% gel, acryla-
mide/bis-acrylamide ratio 100:1) that resolved on the same gel
both b-actin (MW 45 kDa) and ATM (MW 350 kDa). Molecular
weight rainbow standards were from Amersham. Gels were
electroblotted overnight onto polyvinylidene difluoride (PVDF)
membranes (Millipore, Bedfored, MA, USA) in 25 mM Tris, 
192 mM Glycine pH 8, 20% methanol at 300–400 mA. After
blocking with 5% non-fat dried milk in PBS plus 0.1% Tween-20
(PBS-T) (Sigma), membranes were cut into two halves by the 220
kDa marker, and incubated for 3 h with the anti-ATM antibody
(upper half) and the anti b-actin (Sigma) (lower half) diluted in
TBS-T plus 5% milk. After rinsing in PBS-T and incubation for 1
h with 1:3000 dilution of peroxidase-labelled secondary antibody,
membranes were rinsed again and revealed by ECL-plus
(Amersham) and autoradiography. Western analysis for p53 were
performed on lysates from cells harvested before and 3 h after 
400 rads g-radiation, and separated on 12% SDS-PAGE. The phos-
phorylation of p53 at serine 15 was detected using a phosphospe-
cific rabbit antibody (Shieh et al, 1997), and total p53 using the
monoclonal antibody DO7. Autoradiographs were scanned and
quantitated using ImageQuant (Molecular Dynamics, Sunnyvale,
CA, USA).
RESULTS
ATM protein levels in AT patients and AT heterozygotes
Eighteen AT cases were included in this study, five homozygous
(AT9RM, AT21RM, AT32RM, AT43RM, AT44RM and
AT74RM) and nine compound heterozygous (AT15RM, AT35RM,
AT52RM, AT57RM, AT58RM, AT65RM, ATJ1 and the siblings
AT28RM and AT54RM) for ATM gene mutations predicted to
result in protein truncation in all but AT21RM, the latter bearing a
90 nt deletion mutation causing exon 18 skipping (Table 1).
Mutations in the remaining cases are currently unknown. On
Western blots (Table 1 and Figure 1), ten cases were negative,
whereas seven others evidenced a normal size ATM protein band
whose intensity was 1 ¸ 32% of normal cells. A truncated ATM
product of ~270 kDa was detected in ATJ3 (Figure 1, bottom), a
case with an unknown gene mutation. Low amounts 
of ATM protein were observed in A(-T) 6RM (20%), but not in A(-
T)5RM (70%). Among AT heterozygotes, ATM gene mutations
were established in eight of ten, all bearing one normal and a
second mutated allele (Table 1). Some of them are obligate
heterozygotes, e.g. 154RM and 155RM are the father and mother
respectively, of AT28RM and AT54RM siblings, while 227RM
and 247RM are fathers of AT43RM and AT44RM respectively. All
cases, except 98RM, expressed lower amounts of ATM protein
than normal controls (e.g. LBC-N and cells from healthy members
of AT families with no ATM mutations such as 242RM and
243RM, both uncles of AT44RM; and 314RM uncle of another AT
ATM protein expression in AT and AT heterozygotes 1939
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exon 18 skipping, the ATM protein was just below normal levels.
Reduced ATM expression was found in two relatives of AT
patients with yet unknown mutations (261RM and 313RM),
suggesting the possibility that these cases are heterozygous for AT.
To rule out the possibility that the differences in ATM expres-
sion between normal and AT heterozygotes were somehow due to
EBV immortalization, protein determinations were performed on
in vitro activated T-cells from parents of two AT cases. It can be
seen (Figure 2) that activated T-cells from the AT heterozygotes
154RM and 155RM exhibited 50% lower levels of ATM protein
than activated T-cells from normal donors.
Phosphorylation of p53 at serine 15
In normal cells, p53 protein becomes rapidly phosphorylated at
serine 15 following DNA damage, whereas in AT cells this event
is defective (Shieh et al, 1997; Siliciano et al, 1997; Nakagawa et
al, 1999). This post-translational modification of p53 is primarily
mediated by ATM, whose kinase activity is markedly enhanced by
treatment with radiomimetic drug (Banin et al, 1998; Canman et
al, 1998). We thus examined the phosphorylation of p53-Ser 15 to
evaluate the activity of ATM in relation to ATM gene mutations
and protein levels. In all cases, unirradiated samples generated a
very faint band on immunoblots probed with an antibody for
phosphoserine 15 of p53 (Shieh et al, 1997). However, at 3 h post
400 rads g-radiation, the phosphorylation band was rather intense,
but according to densitometric analysis the signal intensity in AT
cells was ~60% lower than in normal cells (Figure 3 and 4), irre-
spective of the amount of endogenous ATM protein (e.g. compare
AT65RM with AT21RM). Abnormal p53-Ser15 phosphorylation
levels were also found in A(-T)5RM, raising the possibility that
the kinase activity of the ATM protein expressed by this case (65%
of the normal levels) is impaired. Among four heterozygotes, 
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Table 1 ATM genomic mutations, protein levels and cell cycle analysis in cells from AT patients, AT-heterozygotes and
normal individuals
ATM G1/G2-Me
Case ATM genomic mutations protein
levelsc
AT9RM 9139 CÕT 0.07 0.34±0.064 (3)
AT15RM 129TÕC / ? 0.02 0.8
AT21RM IVS18 + 1 del G 0.32 0.88±0.29 (3)
AT27RM NA <0.03 0.69±0.17 (3)
AT28RMb 7792 CÕT / 8283 del TC neg 1.04±0.33 (4)
AT32RM 3802 del G <0.03 ND
AT35RM 3576 GÕA / 5574 GÕA <0.02 0.83±0.16 (3)
AT43RM 7517 del 4 Neg 0.77±0.41 (3)
AT44RM IVS 12 + 1 GÕT Neg 0.6
AT52RM 7327 CÕT / 8365 del A Neg 0.93±0.23 (4)
AT54RMb 7792 CÕT / 8283 del TC Neg 0.95±0.07 (3)
AT57RM 7517 del 4 / ? Neg 0.33±0.07 (3)
AT58RM 2250 GÕA / ? Neg ND
AT65RM IVS47 –9 GÕA / 8814 del 11 Neg 0.61±0.13 (3)
AT68RM NA Neg 1
AT74RM [3993ins29]a 0.15±0.02 ND
ATJ1 7519 del GA / ? <0.02 ND
ATJ3 NA 0.29d 0.7
A(-T)5RM NA 0.7±0.1 0.66±0.15 (3)
A(-T)6RM NA 0.20 1.15±0.1 (4)
75RM 3894ins T / N 0.53 1.75±0.2 (3)
98RM IVS 18 + 1 del G / N 0.9±0.1 0.99±0.15 (4)
154RM 8283 del TC / N 0.5 ND
155RM 7792 CÕT / N 0.45±0.18 1.67±0.09 (3)
227RM 7517 del 4 / N 0.40±0.14 1.12±0.17 (4)
247RM IVS12 + 1 GÕT / N 0.45±0.31 1.88±0.40 (4)
373RM 8283 del TC / N 0.59±0.4 2.1±0.24 (3)
261RM NA 0.57±0.13 2.15±0.63 (3)
262RM 3802 del G / N 0.52 0.88±0.16 (5)
313RM NA 0.35±0.28 1.9
242RM N 1.01±0.07 2.1±1.0 (5)
243RM N 1 1.57±0.81 (4)
314RM N 1.2±0.2 2.7±0.59 (3)
LBC-N N 1 2.18±0.53 (9)
N, normal allele or normal case; NA, mutation not available or not yet identified. aMutation position referred to the cDNA;
bsibs; c the ATM intensity values were calculated from densitometric analysis of Western blot autoradiographic films, after
correction for protein content using b-actin as a marker (see Materials and Methods) and normalization against normal LBC-
N cells. The average intensity ± s.d. has been determined on cases analysed 3 or more independent times. dValue referred
to the truncated ATM protein. eDNA flow cytofluorimetric analysis were performed on propidium iodide stained cells 24 h
after exposure (or not, for control) to 400 rads of g-radiation. The fractions of G1 and G2-M cells were determined by CellFIT
software analysis of the acquired DNA histograms (20 000 events/sample). For cases analysed multiple times, the G1/G2-M
ratio (average ± s.d.) is shown together with the number of independent measurements (in parenthesis).ATM protein expression in AT and AT heterozygotes 1941
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p53-Ser15 phosphorylation levels were normal in 98RM and
247RM, but reduced by 20 and 60% in 227RM and 373RM
respectively. Of these cases, the latter three expressed reduced
amounts of ATM protein. It should be noticed that the partial phos-
phorylation of p53-Ser15 in ATM negative cases most likely
reflects the activity of the AT- and Rad-3-related ATR kinase,
reported to phosphorylate this residue, though less efficiently than
ATM (Canman et al, 1998; Lakin et al, 1999).
We also performed, in some cases, time-course analysis to
determine if the phosphorylation of p53-Ser15 in cells with inac-
tive ATM was somehow delayed. The results (Figure 5) showed
that in LBC-N normal cells p53-Ser15 phosphorylation levels
remained maximal and stable between 3 and 6 h post irradiation,
to decline 10 h later by ~50%. Conversely, in ATJ3 p53-Ser15
phosphorylation progressively increased and by 10 h its levels
were comparable to those seen in normal cells at 3 h post-treat-
ment. In A(-T)5RM the trend of p53-Ser15 phosphorylation was
similar to that of normal cells, except that at all time-points the
signal intensity was reduced.
Cell cycle analysis
In response to DNA damage, whereas normal cells arrest in G1,
cells from AT cells patients do not because of a G1 cell cycle
checkpoint defect. This abnormality, associated with an insuffi-
cient accumulation of p53 protein and poor induction of its target
gene p21waf1 (Canman et al, 1994; Khanna et al, 1995) can be
corrected by enforced expression of functional ATM (Zhang et al,
1997; Ziv et al, 1997).
We analysed the flow cytofluorimetric DNA profile of cells before
and 24 h after treatment with 400 rads of g-radiation to evaluate the
G1 checkpoint function. In all AT and A(-T) cases, irradiation caused
a significant reduction of the fraction of G1 and a concomitant
increase of G2-M phase cells, and therefore an inversion of the
G1/G2-M ratio (Table 1), in marked contrast to the modest redistrib-
ution of these cell cycle phases in normal cells (G1/G2-M ratio: 2.18
± 0.53). Of note, in AT samples the magnitude of the G1 defect was
similar, whether or not they expressed ATM protein, suggesting that
protein is ineffective. Among eight AT heterozygotes, the G1 check-
point was abnormal in 98RM, 262RM and 227RM.
Altogether, these evidences lead to conclude the G1 checkpoint
is invariably disrupted in AT and A(-T) cases, and this defect 
is not alleviated by the expression of limiting amounts of ATM
protein. In AT heterozygotes, the G1 checkpoint is less frequently
abnormal (three of eight cases examined), but no clearcut correla-
tion with the type of ATM mutations has been established.
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Figure 1 ATM protein levels in lymphoblastoid cells from normal donors, AT
patients and carriers. Western blots were performed as detailed in Materials
and Methods, using a two-gradient SDS-PAGE in order to recover on the
same membrane both ATM and b-actin. After electroblotting, the upper part
of the membrane was tested for ATM and the lower part for b-actin. Binding
of antibodies to the membrane was detected by ECL. ATJ3.1 (bottom figure)
is the brother of ATJ3
Figure 3 Radiation-induced phosphorylation of p53 on Serine 15 in AT, 
A(-T) and heterozygotes. Cells were harvested 3 h after treatment (or not, 
for control) with 400 rads of g-radiation, lysed and analysed for p53-Ser 15
phosphorylation by Western blot using a phosphospecific rabbit antibody
(see Materials and Methods) and ECL detection. Blots were reprobed for 
b-actin for normalization
Figure 2 ATM protein in activated blood lymphocytes. PBMC from normal
donors and AT heterozygotes were activated in vitro with TPA-ionomycin for
4 days, thereafter lysed and analysed for ATM by Western blottingDISCUSSION
The identification of the ATM gene (Savitsky et al, 1995a, 1995b)
is providing new insights for the comprehension of the molecular
events that account for the AT phenotype and the role of this gene
in genomic instability and cancer predisposition. ATM is believed
to be the most common cancer susceptibility gene, since ~ 1% of
the general population are heterozygous carriers (Swift et al, 1986;
Tchirkov et al, 1997), and these people are at increased risk of
cancer (Swift et al, 1991). The suggested relationship between AT
heterozygosity and predisposition to early onset of breast cancer
remains debated (Swift et al, 1986; Athma et al, 1996; FitzGerald
et al, 1997; Janin et al, 1999).
In this study we analysed the ATM expression in lymphoblas-
toid cells derived from healthy and affected members of AT fami-
lies in relation to the ATM gene mutations. Variable amounts of
full-length ATM protein were found among AT, with ten cases
negative and eight showing 1–32% of normal. However, none of
the cases, except ATJ3, evidenced truncated ATM proteins despite
the prevalence of ATM gene mutations expected to yield polypep-
tides truncated downstream of the epitope recognized by the anti-
ATM antibody in this regard, our data agree with others showing
minimal or no ATM protein expression in AT cells affected by
different truncation mutations (Lakin et al, 1996; Watters et al,
1997; Gilad et al, 1998; Teraoka et al, 1999). We cannot currently
exclude that the lack of protein may reflect a truncation-related
instability that affects both the ATM transcript and protein
product, according to RT-PCR analysis on AT44RM (and its
family members), in which the mutant mRNA accumulates to 60%
of the normal levels (data not shown), even though no ATM
protein is detected.
ATJ3 (and its affected family member ATJ3.1) was the only
case showing a truncated protein, suggesting that the as yet
unknown ATM mutation of this case might have milder effect on
the destabilization of the transcript and/or protein.
1942 D Delia et al
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Figure 4 Levels of phosphorylated p53-Ser15 in AT, A(-T) and heterozygotes in relation to ATM protein. The phosphorylation of p53-ser15 was detected by
Western analysis (see legend to Figure 3), and quantitated by scanning densitometry of autoradiographic films. The p53-Ser15 values were corrected for b-actin
content, and normalized to those of LBC-N normal cells. The ATM values are those reported in Table 1
LBC-N A(-T)5RM ATJ3
p53-P-Ser15
b-actin
Time (h) 0 3 6 10 0 3 6 10 0 3 6 10
Figure 5 Time-dependent phosphorylation of p53-Ser15 in response to
DNA damage. Cells, unirradiated or harvested at the indicated time-points
after 400 rads g-radiation, and analysed by Western blotting with antibodies
to p53 phosphorylated on Ser 15 and to b-actinOur data showing modest amounts of full-length ATM protein
in cases bearing truncation mutations are concordant with those of
Gilad et al (1998) and have been previously explained by the
‘leakiness’ of these mutations, therefore allowing expression of
low levels of ATM protein (Gilad et al, 1998). The residual expres-
sion of ATM protein in some AT patients appears associated with a
milder disease progression (Gilad et al, 1998).
We have shown that the ATM protein content in AT heterozy-
gotes is ~40–50% lower than normal controls, in agreement with
our previous report based on a smaller number of cases (Shigeta et
al, 1999). A reasonable explanation for this haplo-insufficiency
may lie in the fact that truncation mutation alleles are poorly
expressed (as in AT), and thus the total amount of ATM protein in
AT heterozygotes mostly accounts for by the expression of the
wild-type allele. ATM protein deficit was also found in activated
blood T-lymphocytes from the obligate heterozygotes 154RM and
155RM, strongly suggesting that, at least in these cases, the differ-
encies in ATM expression among EBV-immortalized lympho-
blastoid cells are real. However, we cannot exclude a certain
cell-to-cell line variable influence of EBV on ATM that could
account for the observed wide range of protein expression.
The evidence that AT heterozygotes are more radiosensitive
than normal donors (West et al, 1995; Scott et al, 1996; Tchirkov 
et al, 1997; Shigeta et al, 1999) has led to suggestions that the
increased risk of cancer in these individuals arises from a partial
defect of the gene responsible for AT. Since ATM plays a central
role in cell cycle checkpoint responses to DNA damage (Canman
et al, 1994; Khanna et al, 1995), we determined the G1 checkpoint
function in relation also to ATM protein levels. None of the AT and
A(-T) cases analysed arrested in G1 after irradiation, and further-
more, the magnitude of this abnormality did not correlate with the
levels of endogenous ATM protein (compare cases negative, e.g.
AT57RM, AT54RM, and positive, e.g. AT9RM, AT21RM for
ATM protein). This finding would suggest that either the amount
of ATM protein in these cases is insufficient to exert a phenotypic
effect (in which case A(-T)5RM would represent an exception as it
shows 70% of the normal levels of ATM but a defective G1 check-
point), or that the ATM protein is intrinsically inactive. Three of
eight AT heterozygous cases showed an abnormal G1 checkpoint,
two of them with ~50% (227RM and 262RM) and one (98RM)
with almost normal levels of ATM protein. Interestingly, 98RM is
the father of AT21RM, the latter bearing a homozygous mutation
causing exon 18 deletion and expressing intermediate levels of
ATM (~32% of normal). Whether in this case the mutant protein
exerts a dominant negative effect over the wild-type allele, as in
the case ATM proteins mutant in the leucine zipper motif (Morgan
et al, 1997), is a possibility that requires further investigation.
The fact that many AT carriers exhibit a normal G1 checkpoint,
in spite of the reduced ATM expression, suggests that in heterozy-
gosity this level of endogenous protein is still able to provide a
normal regulation of the ATM- and p53-dependent G1 cell cycle
checkpoint. We cannot, however, exclude that ATM haplo-insuffi-
ciency may affect the S phase checkpoint responsible for the inter-
mediate radiosensitivity in AT heterozyygotes (West et al, 1995;
Scott et al, 1996; Tchirkov et al, 1997).
In response to DNA damage, p53 undergoes phosphorylation at
multiple sites, including serine 15. The phosphorylation of this
residue alleviates the binding of p53 to MDM2 and allows p53
itself to accumulate and to exert its function (Shieh et al, 1997).
p53-Ser15 phosphorylation is mediated in vitro and in vivo, by the
kinases ATM and ATR, whose activities are enhanced by treatment
of cells with DNA damaging agents (Banin et al, 1998; Canman et
al, 1998; Lakin et al, 1999). It should be noticed however, that
while ATM acts immediately after DNA damage, ATR acts at a
later time and less efficiently that ATM. We have shown here that
although DNA damage induced p53-Ser15 phosphorylation in AT
and A(-T) cells, nevertheless, compared to normal cells, the
magnitude of this event at 3 h was reduced by ~60% even in cases
bearing some ATM protein (e.g. AT65RM vs AT21RM). Two
conclusions can be drawn from these results. The first, based on
the partial phosphorylation p53-Ser 15 in ATM null cells, which
further supports the role in vivo of an additional kinase, most
likely ATR (Canman et al, 1998; Lakin et al, 1999; Tibbets et al,
1999), in the phosphorylation of p53. The second, that the ATM
protein in AT or A(-T) cases is dysfunctional since its presence
was not associated with an increased p53-Ser 15 phosphorylation.
The p53-Ser15 phosphorylation in four heterozygotes (three of
them showing diminished ATM expression) have shown normal
regulation in two, but reduced by 20% and 60% in the other two
cases, suggesting that in heterozygosity (wt/mut) the ATM protein
can provide a normal function even if present at half the normal
levels (e.g. 247RM), although in some cases and for unknown
reasons, this may not be so (e.g. 373RM). It is worthnoting that
discrepancies between p53-Ser15 phosphorylation and G1 check-
point control have been found in some cases (e.g. 373RM, 98RM
and 227RM, the former exhibiting low Ser 15 phosphorylation and
normal G1 arrest, and vice versa for the latter two). Currently we
have no explanation for this and we can only hypothesize, in the
case of 98RM and 227RM the existence of additional abnormali-
ties in the p53-response pathway that can contribute to these find-
ings.
The analysis of p53 regulation after DNA damage have shown
interesting differences in the kinetics of p53-Ser 15 phosphoryla-
tion in AT cells. In fact, while in normal cells this phosphorylation
becomes maximal at 3 h and starts to decline at 10 h, in ATJ3,
which express a truncated and apparently inactive ATM protein,
these maximal levels of p53-Ser 15 phosphorylation are seen only
10 h after irradiation. Interestingly, however, in A(-T)5RM cells
which express 70% of the normal ATM levels, the time-dependent
phosphorylation changes parallel those of normal cells, but the total
levels of p53-Ser15 phosphorylation remain lower at all time-points
examined. These findings would thus suggest an association
between defective G1 checkpoint and suboptimal phosphorylation
of p53-Ser 15 during the early hours post DNA damage.
In conclusion, we have demonstrated that AT and A(-T) cells
frequently express modest amounts of full-length (and only rarely
truncated) ATM protein, despite the elevated frequency of trunca-
tion mutations of the ATM gene. When expressed, this full-length
ATM protein may be intrinsically defectivel or quantitatively insuf-
ficient for the normal regulation of the p53-dependent G1 cell cycle
checkpoint. We have also shown that AT heterozygotes express
50–60% of the normal ATM levels, but this deficit alone is insuffi-
cient to impair the G1 checkpoint. Other factors, including the type
of wt/mut ATM mutations, could thus contribute to this defect.
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